BioRegenx, Inc.
BRGX
$0.01
$0.0013.92%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.26% | -14.80% | -39.24% | -6.26% | -32.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.26% | -14.80% | -39.24% | -6.26% | -32.08% |
| Cost of Revenue | -51.45% | -28.85% | -64.61% | -34.04% | -54.07% |
| Gross Profit | -1.21% | -11.46% | -24.98% | 5.67% | -14.63% |
| SG&A Expenses | -70.27% | 76.14% | -69.55% | -82.72% | 216.28% |
| Depreciation & Amortization | -104.45% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.75% | -44.09% | -68.81% | -80.50% | 188.30% |
| Operating Income | 89.99% | 97.40% | 89.68% | 93.75% | -894.42% |
| Income Before Tax | 94.47% | 79.59% | 83.88% | 91.53% | -7,068.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 94.47% | 79.59% | 83.88% | 91.53% | -7,068.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.47% | 79.59% | 83.88% | 91.53% | -7,068.13% |
| EBIT | 89.99% | 97.40% | 89.68% | 93.75% | -894.42% |
| EBITDA | 88.71% | -98.42% | 85.13% | 93.01% | -627.04% |
| EPS Basic | 94.84% | 75.00% | 83.33% | 92.68% | -5,225.00% |
| Normalized Basic EPS | 87.50% | 66.67% | 85.71% | 92.31% | -700.00% |
| EPS Diluted | 94.84% | 75.00% | 83.33% | 92.68% | -5,225.00% |
| Normalized Diluted EPS | 87.50% | 66.67% | 85.71% | 92.31% | -700.00% |
| Average Basic Shares Outstanding | 11.42% | 0.45% | 0.28% | 24.67% | 23.86% |
| Average Diluted Shares Outstanding | 11.42% | 0.45% | 0.28% | 24.67% | 23.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |